Varnimcabtagene Autoleucel (Var-Cel) and NexCAR19 Transform India's CAR T-Cell Therapy Market | Breakthroughs by Immuneel Therapeutics & ImmunoACT, Investment Trends, and Market Growth

India's Advancements in CAR T-Cell Therapy | Market Impact, Investment Opportunities, and Future Growth

Varnimcabtagene Autoleucel (Var-Cel) | A Major Breakthrough in Indian Oncology

Approval and Clinical Trials

In January 2025, India's Central Drugs Standard Control Organization (CDSCO) approved varnimcabtagene autoleucel (var-cel), a CD19-targeted CAR T-cell therapy, for adult patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.

Marketed as Qartemi by Immuneel Therapeutics, this therapy represents a significant advancement in India's cancer treatment landscape.

The approval was based on the Phase 2 IMAGINE trial conducted across multiple hospitals in India.

The study reported an 83.3% overall response rate (ORR) at 90 days post-treatment, indicating substantial efficacy in the target patient population.

Source: January 2025, "India Approves First CAR-T Therapy Qartemi for B-Cell Non-Hodgkin's Lymphoma"

You can gain detailed market insights with the Free Sample Copy of our expertly prepared CAR T-Cell Therapy Market Research Report: https://www.marketdigits.com/request/sample/35

Development and Collaboration

Var-cel is notable for being India's first CAR T-cell therapy benchmarked to global standards.

Immuneel Therapeutics licensed the therapy from Hospital Clínic de Barcelona, where initial preclinical and Phase 1 studies were conducted.

This international collaboration underscores the therapy's robust development process and India's growing role in the global biotech sector.

Source: January 2025, "India Approves First CAR-T Therapy Qartemi for B-Cell Non-Hodgkin's Lymphoma"

Accessibility and Cost

Addressing the financial challenges often associated with CAR T-cell therapies, Immuneel Therapeutics has priced Qartemi between ₹35 lakhs to ₹50 lakhs (approximately $42,000 to $60,000) per dose.

While this reflects the complexity of manufacturing personalized CAR T-cell therapies, it remains significantly more affordable than similar treatments available globally, which can cost upwards of $400,000 per dose.

Source: January 2025, "India Approves First CAR-T Therapy Qartemi for B-Cell Non-Hodgkin's Lymphoma"

Hospital Partnerships

To facilitate widespread access, Immuneel has partnered with leading hospitals across India, including Narayana Health, Apollo Hospitals, CMC Vellore & Ludhiana, Manipal Hospitals, and others.

These collaborations aim to ensure that patients nationwide can benefit from this advanced therapy.

Source: Delta Larvol, February 2025, "Indian Hospitals Collaborate for Nationwide CAR-T Cell Therapy Accessibility"

Actalycabtagene Autoleucel (NexCAR19) | India's First Homegrown CAR T-Cell Therapy

Development and Approval

NexCAR19, India's first homegrown CAR T-cell therapy, was approved by CDSCO in October 2023 for treating advanced B-cell lymphoma and leukemia.

This therapy marks a milestone in India's biopharmaceutical sector, highlighting the country's capability to develop world-class cell and gene therapies.

Source: National Cancer Institute (NCI), February 2025, "NexCAR19: India's First Homegrown CAR T-Cell Therapy Gains Global Attention"

Clinical Trial Outcomes

In clinical trials involving 64 patients, NexCAR19 achieved an overall response rate (ORR) of 67%, with approximately 50% of participants experiencing complete remission.

Notably, severe neurotoxicity was absent, and only 5% of patients experienced severe cytokine release syndrome (CRS).

These safety data reinforce the treatment's potential as an effective and well-tolerated option.

Source: National Cancer Institute (NCI), February 2025, "NexCAR19: India's First Homegrown CAR T-Cell Therapy Gains Global Attention"

Cost and Production

Manufactured by ImmunoACT, a spin-off from IIT Bombay, NexCAR19 is priced around $50,000 per dose, making it more affordable compared to international alternatives.

The local production significantly reduces dependency on expensive imports, improving accessibility for Indian patients.

Source: National Cancer Institute (NCI), February 2025, "NexCAR19: India's First Homegrown CAR T-Cell Therapy Gains Global Attention"

Government Initiatives and Future Outlook

The Indian government has been actively promoting research and development in CAR T-cell therapies.

Collaborations between institutions like IIT Bombay and Tata Memorial Centre have been pivotal in advancing these treatments.

Government funding and private investments are expected to accelerate innovation and commercialization in the Indian CAR-T market.

Source: Ministry of Health and Family Welfare (MOHFW), February 2025, "India's Commitment to Cell & Gene Therapy Innovation"

Market Growth, Investment Potential, and Industry Implications

Impact on CAR T-Cell Therapy Market Growth

The approval of var-cel and NexCAR19 signals rapid growth in India's CAR T-cell therapy market, with increasing demand for personalized oncology treatments.

With India's biotech industry expanding and domestic production lowering costs, the market is expected to grow at a CAGR of over 15% between 2025 and 2030.

View the complete 180 Pages Market Research Report on CAR T-Cell Therapy: https://www.marketdigits.com/car-t-cell-therapy-market

Investment Opportunities

Investors can capitalize on India's emerging CAR-T sector through:

Biotech and pharmaceutical stocks: Companies like Immuneel Therapeutics and ImmunoACT offer strong investment potential.
Healthcare infrastructure: Expansion of specialized CAR-T treatment centers presents investment avenues in hospital chains.
R&D funding: Startups and research institutions engaged in gene therapy are likely to attract venture capital funding.
Source: Ministry of Health and Family Welfare (MOHFW), February 2025, "India's Commitment to Cell & Gene Therapy Innovation"

The approval and commercialization of varnimcabtagene autoleucel (var-cel) and actalycabtagene autoleucel (NexCAR19) mark a new era in India's oncology treatment landscape.

With improved accessibility, government support, and growing investor interest, India's CAR T-cell therapy market is poised for exponential growth in the coming years.

The country's emphasis on affordable innovation, international collaborations, and local production positions it as a key player in the global cell and gene therapy industry.

About Us

Founded in 2015, MarketDigits Consulting & Advisory Pvt Ltd is a leading business research and consulting firm. Our mission is to empower clients by identifying emerging opportunities and driving revenue growth across industries. We specialize in providing comprehensive market insights, advanced technology solutions, and actionable strategies that support operational and strategic decision-making.

With a focus on the full value chain, our expert team delivers high-quality syndicate research reports, proprietary databases, and consulting services to help clients navigate today's competitive and dynamic business environment. At MarketDigits, we use advanced analysis to uncover profitable opportunities, enabling businesses to make smart decisions and achieve sustainable success.

Contact Us:

+1 510-730-3200 | +1 276-206-2055

sales@marketdigits.com

1248 CarMia Way Richmond

VA 23235, United States

This release was published on openPR.